Long-term follow-up of the risk for cervical intraepithelial neoplasia grade 2 or worse in HPV-negative women after conization

International Journal of Cancer

Volumn 137, Issue 12, 2015, Pages 2927-2933

  Gosvig, Camilla F ^a   Huusom, Lene D ^a   Andersen, Klaus K ^a   Duun Henriksen, Anne Katrine ^a   Frederiksen, Kirsten ^a   Iftner, Angelika ^b   Svare, Edith ^c   Iftner, Thomas ^b   Kjaer, Susanne K ^a,d  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c Private Gynecological Clinic   (Denmark)

^d University of Copenhagen   (Denmark)

Author keywords

cervical intraepithelial neoplasia; conization; human papillomavirus; long term follow up

Indexed keywords

ADULT; ARTICLE; CANCER GRADING; CANCER RISK; CANCER SCREENING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CONIZATION; UTERINE CERVIX CYTOLOGY; WART VIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PREVENTION AND CONTROL; PROSPECTIVE STUDY; TUMOR RECURRENCE; UTERINE CERVIX; VIROLOGY; YOUNG ADULT;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; CONIZATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84943641998     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29673     Document Type: Article

References (20)

1. Martin-Hirsch PP, Paraskevaidis E, Bryant A, et al., Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev 2013; 12: CD001318
2. Melnikow J, McGahan C, Sawaya GF, et al., Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study. J Natl Cancer Inst 2009; 101: 721-8
3. Strander B, Ryd W, Wallin KL, et al., Does HPV-status 6-12 months after treatment of high grade dysplasia in the uterine cervix predict long term recurrence? Eur J Cancer 2007; 43: 1849-55
4. Katki HA, Schiffman M, Castle PE, et al., Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management. J Lower Genital Tract Dis 2013; 17: S78-84
5. Kocken M, Helmerhorst TJ, Berkhof J, et al., Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol 2011; 12: 441-50
6. Kjaer SK, Frederiksen K, Munk C, et al., Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010; 102: 1478-88
7. Thomsen LT, Frederiksen K, Munk C, et al., High-risk and low-risk human papillomavirus and the absolute risk of cervical intraepithelial neoplasia or cancer. Obstet Gynecol 2014; 123: 57-64
8. Gosvig CF, Huusom LD, Andersen KK, et al., Persistence and reappearance of high-risk human papillomavirus after conization. Gynecol Oncol 2013; 131: 661-6
9. Kjaer SK, Munk C, Junge J, et al., Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention? Cancer Causes Control 2014; 25: 179-89
10. Solomon D, Davey D, Kurman R, et al., The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114-9
11. Bjerregaard B, Larsen OB., The Danish pathology register. Scand J Public Health 2011; 39: 72-4
12. Kitchener HC, Walker PG, Nelson L, et al., HPV testing as an adjunct to cytology in the follow up of women treated for cervical intraepithelial neoplasia. Br J Obstet Gynaecol 2008; 115: 1001-7
13. Kocken M, Uijterwaal MH, de Vries AL, et al., High-risk human papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical disease: a systematic review and meta-analysis. Gynecol Oncol 2012; 125: 500-7
14. National Health Service Cervical Screening Programmes. Evaluation of sentinel sites for HPV triage and Test of Cure. Sheffield; 2011
15. Kelly RS, Patnick J, Kitchener HC, et al.,; Group NHSI. HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the sentinel sites study. Br J Cancer 2011; 105: 983-8
16. van der Heijden E, Lopes AD, Bryant A, et al., Follow-up strategies after treatment (large loop excision of the transformation zone (LLETZ)) for cervical intraepithelial neoplasia (CIN): impact of human papillomavirus (HPV) test. Cochrane Database Syst Rev 2015; 1: CD010757
17. Wang SS, Gonzalez P, Yu K, et al., Common genetic variants and risk for HPV persistence and progression to cervical cancer. PloS One 2010; 5: e8667
18. Einstein MH., Women whose cervical intraepithelial neoplasia has been treated or resolved remain at continued high risk for cervical cancer. Evidence-Based Med 2013; 18: 190-1
19. Kadish AS, Ho GY, Burk RD, et al., Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J Natl Cancer Inst 1997; 89: 1285-93
20. Rebolj M, Helmerhorst T, Habbema D, et al., Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study. BMJ 2012; 345: e6855